These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

818 related items for PubMed ID: 28596108

  • 41. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M.
    BMC Cancer; 2018 Jan 30; 18(1):106. PubMed ID: 29382302
    [Abstract] [Full Text] [Related]

  • 42. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.
    Ann Oncol; 2013 Aug 30; 24(8):2080-7. PubMed ID: 23559152
    [Abstract] [Full Text] [Related]

  • 43. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr 30; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 44. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep 30; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 45. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, Tomii K, Katakami N.
    Lung Cancer; 2014 Nov 30; 86(2):213-8. PubMed ID: 25304185
    [Abstract] [Full Text] [Related]

  • 46. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM, Park K.
    Curr Opin Oncol; 2017 Mar 30; 29(2):89-96. PubMed ID: 28085680
    [Abstract] [Full Text] [Related]

  • 47. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS, Cho BC, Soo RA.
    Lung Cancer; 2016 Mar 30; 93():59-68. PubMed ID: 26898616
    [Abstract] [Full Text] [Related]

  • 48. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
    Castellanos EH, Horn L.
    Curr Treat Options Oncol; 2015 Oct 30; 16(10):51. PubMed ID: 26364032
    [Abstract] [Full Text] [Related]

  • 49. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 30; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 50. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
    Giuliani J, Martelli S, Remo A, Bonetti A.
    Tumori; 2015 Jul 24; 101(4):e115-7. PubMed ID: 25953440
    [Abstract] [Full Text] [Related]

  • 51. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM.
    Lung Cancer; 2017 Feb 24; 104():58-64. PubMed ID: 28213001
    [Abstract] [Full Text] [Related]

  • 52. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 53. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, Delmonte A, Giovannini M, Spaggiari L, de Braud F, Barberis M.
    J Thorac Oncol; 2011 Nov 26; 6(11):1895-901. PubMed ID: 21841502
    [Abstract] [Full Text] [Related]

  • 54. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
    Cadranel J, Ruppert AM, Beau-Faller M, Wislez M.
    Crit Rev Oncol Hematol; 2013 Dec 26; 88(3):477-93. PubMed ID: 23911281
    [Abstract] [Full Text] [Related]

  • 55. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
    Wang Z, Chen R, Wang S, Zhong J, Wu M, Zhao J, Duan J, Zhuo M, An T, Wang Y, Bai H, Wang J.
    PLoS One; 2014 Dec 26; 9(11):e110780. PubMed ID: 25405807
    [Abstract] [Full Text] [Related]

  • 56. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.
    Lung Cancer; 2015 Mar 26; 87(3):311-7. PubMed ID: 25617986
    [Abstract] [Full Text] [Related]

  • 57. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y, Wang Y, James M, Jeong JH, You M.
    Mol Carcinog; 2016 May 26; 55(5):991-1001. PubMed ID: 26052929
    [Abstract] [Full Text] [Related]

  • 58. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
    Takeda Y, Naka G, Yamaguchi Y, Hashimoto M, Suzuki M, Izumi S, Sugiyama H.
    BMC Cancer; 2020 Oct 02; 20(1):951. PubMed ID: 33008313
    [Abstract] [Full Text] [Related]

  • 59. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY.
    Oncotarget; 2017 Jan 10; 8(2):3412-3421. PubMed ID: 27926500
    [Abstract] [Full Text] [Related]

  • 60. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K.
    Lung Cancer; 2020 Jan 10; 139():28-34. PubMed ID: 31710890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.